Keywords: Exercise; Gait; Posture; Rehabilitation; Walking; EDSS; Expanded Disability Status Scale; MAC; motor adaptation cohort; MS; multiple sclerosis; SOT; Sensory Organization Test; TEC; therapeutic exercise cohort;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Demonstration; EDSS; Validation; WWTP process selection;
Keywords: BSC; Biomass Supply Chain; BSCND; Biomass Supply Chain Network Design; GIS; Geographical Information Systems; EDSS; Environmental Decision Support System; LP; Linear Programming; NLP; Non-linear Programming; MINLP; Mixed Integer Non-linear Programming; MC
Keywords: Disability evaluation; Gait; Multiple sclerosis; Postural balance; Rehabilitation; Treatment outcome; 10MWT; 10-m walk test; 25FWT; 25-foot walk test; 6MWT; 6-minute walk test; BBS; Berg Balance Scale; EDSS; Expanded Disability Status Scale; MDC; minimall
Keywords: AAN; American Academy of Neurology; ABN; Association of British Neurologists; AUD; Australian dollars; CIS; clinically isolated syndrome; CNS; central nervous system; DMT; disease-modifying therapy; EDSS; Kurtzke Expanded Disability Status Scale; EMA; Eur
Keywords: Multiple sclerosis; Reactive oxygen species; Carbonyl stress; Saliva; EDSS
Keywords: pwMS; Persons with Multiple Sclerosis; MS; Multiple Sclerosis; CNS; Central Nervous System; D-ER; Dalfampridine-Extended Release; FDA; Food and Drug Administration; T25FW; Timed 25-Foot Walk; Kv; potassium; 4-AP; 4-Aminopyridine; 6Â MW; Six Minute Walk; S
Keywords: QSM; quantitative susceptibility mapping; EDSS; Expanded Disability Status Scale; PRELUDE; Phase Region Expanding Labeller for Unwrapping Discrete Estimates; SHARP; Sophisticated Harmonic Artifact Reduction for Phase data; RESHARP; Regularization Enabled
Keywords: Management strategy evaluation; Simulation interface; User interactivity; Interaction; Learning; Decision support system; DSS; EDSS; Water quality; South East Queensland;
Keywords: Cardiopulmonary exercise test; Multiple sclerosis; Physical fitness; Rehabilitation; Safety; ATS/ACCP; American Thoracic Society/American College of Chest Physicians; CPET; cardiopulmonary exercise testing; ECG; electrocardiogram; EDSS; Expanded Disabilit
Keywords: Multiple sclerosis; Restless legs syndrome; Polysomnography; Periodic leg movements; International Restless Legs Syndrome Study Group questionnaire; AASM; American Academy of Sleep Medicine; AHI; apnea-hypopnea index; CI; confidence interval; EDSS; Expa
Keywords: 4-AP; 4-aminopyridine; APC; antigen presenting cell; ApoE; apolipoprotein E; ATRA; all-trans-retinoic acid; BBB; blood brain barrier; BBI; Bowman-Birk inhibitor; CB1/2; cannabinoid receptor; CBD; cannabidiol; CNS; central nervous system; DC; dendritic c
Keywords: BICAMS; Brief International Cognitive Assessment for Multiple Sclerosis; BVMT-R; Brief Visuospatial Memory Test-Revised; CVLT-II; California Verbal Learning Test-Second Edition; DAF; disease activity-free status; EDSS; Expanded Disability Status Scale; MA
Keywords: Primary progressive multiple sclerosis; Secondary progressive multiple sclerosis; Clinical course; Observational study; EDSS; T25FW;
Keywords: Insulin resistance; Oxidative stress; Multiple sclerosis; EDSS; Cytokines
Keywords: MS; Multiple Sclerosis; RT; Reaction Time; EDSS; Expanded Disability Status Scale; FSS; Fatigue Severity Scale; Multiple Sclerosis; Reaction Time; Fatigue; Walking; Motor Skills; Visual Motor Co-ordination;
Keywords: Multiple sclerosis; Postural balance; Rehabilitation; BBTW; balance-based torso-weighting; COP; center of pressure; EC; eyes closed; EDSS; Expanded Disability Status Scale; EO; eyes open; MS; multiple sclerosis;
Keywords: Complementary and alternative medicine; Multiple sclerosis; Longitudinal study; EDSS; BDI;
Keywords: SRTT; serial reaction time task; PwMS; patients with multiple sclerosis; MS; multiple sclerosis; EDSS; Expanded Disability Status Scale; C; control subjects; exp; explicit; imp; implicit; RT; response time; R; random blocks; S; sequence blocks; NSL; nonsp
Keywords: ADCC; antibody-dependent cellular cytotoxicity; AQP4; aquaporin-4; BSA; bovine serum albumin; CDC; complement-dependent cytotoxicity; CNS; central nervous system; dSTORM; direct stochastic reconstruction microscopy; EDSS; expanded disability status scale;
Keywords: MS; multiple sclerosis; NMO; neuromyelitis optica; NK; natural killer cells; EDSS; expanded disability status scale; WBC; white blood cells; Multiple sclerosis; Demyelinating diseases; Immunology; Rituximab; Monoclonal antibodies; Neuromyelitis optica;
Keywords: DBS; deep brain stimulation; EDSS; expanded disability status scale; IASP; International Association for the Study of Pain; LUTS; lower urinary tract symptoms; MCS; motor cortex stimulation; MS; multiple sclerosis; MS-TN; multiple sclerosis associated tri
Keywords: APCs; antigen presenting cells; EDSS; Expanded Disability Status Scale; ELISA; enzyme-linked immunosorbent assay; IFN; interferon; IFR; interferon regulatory factor; IL; interleukin; PBMCs; peripheral blood mononuclear cells; pDCs; plasmacytoid dendritic
Keywords: BMI; Body Mass Index; CCI; Charlson Comorbidity Index; DMD; Disease Modifying Drug; EDSS; Expanded Disability Status Scale; ER; Emergency Room; NHWS; National Health and Wellness Survey; HRQoL; Health-Related Quality of Life; MCS; Mental Component Summary
Keywords: EDSS; expanded disability status scale; EQ-5D; EuroQuol questionnaire; ETDRS; early treatment diabetic retinopathy study; MRI; magnetic resonance imaging; MS; multiple sclerosis; MSVQ-7; MS-specific vision questionnaire; NARCOMS; North American Research C
Keywords: BBB; blood-brain barrier; CNS; central nervous system; DMF; dimethyl fumarate; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; FDA; Food and Drug Administration; GA; glatiramer acetate; JCV; John Cunningham virus; MRI; magnetic res
Keywords: Accidental falls; Activities of daily living; Multiple sclerosis; Rehabilitation; Self care; EDSS; Expanded Disability Status Scale; FPSS; Fall Prevention Strategy Survey; MS; multiple sclerosis; OHSU; Oregon Health and Science University; PVAMC; Portland
Keywords: Walking impairment; EDSS; Motor function; Spatiotemporal gait parameters;
Keywords: Multiple sclerosis; Disability progression; Interferon beta-1a; EDSS;
Keywords: Mobility limitation; Multiple sclerosis; Physical therapy specialty; Recovery of function; Rehabilitation; CIMT; Constraint-Induced Movement therapy; d'; effect size; EDSS; Expanded Disability Status Scale; FP; functional performance; LE-MAL; Lower Extrem
Keywords: BDNF; brain-derived neurotrophic factor; CSF; cerebrospinal fluid; D-PBS; Dulbecco's phosphate-buffered saline; EAE; experimental allergic encephalomyelitis; EDSS; expanded disability status scale; FACS; fluorescence activated cell sorting; GFAP; glial
Keywords: System dynamics; EDSS; Contaminated sites; Risk-based land management; Uncertainty; Monitored natural attenuation; Human health risk assessment; Vensim;
Keywords: ACC; anterior cingulate gyrus; BOLD; blood-oxygen-level-dependent; DMN; default mode network; EDSS; Expanded Disability Status Scale; EEG; electroencephalography; FC; functional connectivity; fMRI; functional magnetic resonance imaging; HC; healthy contro
The levels of soluble forms of CD21 and CD83 in multiple sclerosis
Keywords: Multiple sclerosis; Soluble CD21; Soluble CD83; EDSS; Epstein Barr virus;
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week
Keywords: AE; adverse event; ARR; annualized relapse rate; CDW; confirmed disability worsening; CI; confidence interval; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; IFN; interferon; IM; intramuscular; IPD; individual patient data; NEDA;
Diagnosis and management of neuromyelitis optica spectrum disorders - An update
Keywords: AQP4; aquaporin-4; AQP4 IgG; immunoglobulin G against aquaporin-4; ARR; Annualized Relapse Rates; AZT; azathioprine; BBB; blood-brain barrier; CNS; central nervous system; EDSS; Expanded Disability Status Scale; GFAP; glial fibrillary acid protein; ICAM1;
The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis
Keywords: Multiple sclerosis; Bayesian Risk Estimate for MS at Onset (BREMSO); Predictive score; Multiple sclerosis severity score (MSSS); Symbol digit modalities test (SDMT); Magnetic resonance imaging (MRI); BREMSO; Bayesian risk estimate for MS at onset; CC; Cor
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Keywords: Disability worsening; Natalizumab; Relapsing-remitting multiple sclerosis; EDSS milestones; CP; cumulative probability; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; RRMS; relapsing-remitting multiple sclerosis; SPMS; secondary p
TNFRSF1A and MEFV mutations in childhood onset multiple sclerosis
Keywords: Multiple sclerosis; Childhood; Familial Mediterranean fever; FMF; Tumor necrosis factor receptor 1-associated periodic syndrome; TRAPS; EDSS; expanded disability status scale; FMF; familial Mediterranean fever; IFNβ; interferon beta; MEFV; Mediterranean
Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder
Keywords: Neuromyelitis optica spectrum disorder; Rituximab; Annual relapse rate; EDSS; Safety;
Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab
Keywords: Neuromyelitis optica spectrum disorders; Human anti-chimeric antibody; Anti-Rituximab antibody; Rituximab; Annual relapse rate; EDSS;
Evidence of axonal damage in cerebellar peduncles without T2-lesions in multiple sclerosis
Keywords: 9-HPT; 9-Hole peg test; AD; Axial diffusivity; CP; Cerebellar peduncle; CSF; Cerebro-spinal fluid; DD; Disease duration; DTI; Diffusion tensor imaging; EDSS; Expanded Disability Status Scale; FA; Fractional anisotropy; FSL; Functional magnetic resonance i
Mutation of the cellular adhesion molecule NECL2 is associated with neuromyelitis optica spectrum disorder
Keywords: Neuromyelitis optica spectrum disorder; NECL2; Gene; Axonal regeneration; Myelination; NMOSD; neuromyelitis optica spectrum disorder; NMO; neurmyelitis optica; CNS; central nervous system; MS; multiple sclerosis; NMO-IgG; NMO immunoglobulin G; HLA; human
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis
Keywords: ab; antibody; ANOS; the overlapping syndrome of AQP4-IgG-positive NMOSD and NMDARe; AQP4; aquaporin-4; CBAs; cell-based assays; CNS; central nervous system; CSF; cerebrospinal fluid; EDSS; Expanded isability Status Scale; IgG; immunoglobulin G; IIFT; immu
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study
Keywords: AE; adverse event; ANCOVA; analysis of covariance; ARR; annualized relapse rate; CI; confidence interval; EDSS; Expanded Disability Status Scale; Gd+; gadolinium-enhancing; iDMT; injectable disease-modifying therapy; MRI; magnetic resonance imaging; MS; m
Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis
Keywords: SIRT1; PBMCs; Multiple sclerosis; Histone trimethylation; Glatiramer acetate; Biomarker; AUC; area under the curve; CNS; central nervous system; CPT; cell preparation tubes; EAE; experimental autoimmune encephalomyelitis; EDSS; expanded disability status
Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients
Keywords: Multiple Sclerosis; B cells; IRF-1; CXCL10 axis; Hsa-miR-424; Transcriptome analysis; CXCL10; C-X-C motif chemokine 10; EBV; Epstein-Barr Virus; IRF1; interferon response factor 1; MS; Multiple sclerosis; RT-PCR; real-time PCR; RR-MS; relapsing remitting
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study
Keywords: ANCOVA; analysis of covariance; CAF; clinical activity-free; CUA; combined unique active; DMD; disease-modifying drug; EDSS; Expanded Disability Status Scale; Gd +;  gadolinium enhancing; IFN β-1a; interferon beta-1a; IM; intramuscularly; ITT; intent-t
Association of serum gamma-glutamyltransferase and C-reactive proteins with neuromyelitis optica and multiple sclerosis
Keywords: GGT; gamma-glutamyltransferase; CRP; C-reactive protein; MS; multiple sclerosis; NMO; neuromyelitis optica; PD; Parkinson disease; EDSS; expanded Disability Status Scale; NMO-IgG; neuromyelitis optic-immunoglobulin; AQP4; aquaporin 4; BBB; blood-brain bar
Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder
Keywords: BBB; blood-brain barrier; CD40L; CD40 ligand; CSF; cerebrospinal fluid; DC; disease control; EDSS; Kurtzke's Expanded Disability Status Scale; HAND; HIV-associated neurocognitive disorder; IL-6; interleukin-6; IQR; interquartile range; MS; multiple scle